Loading...
•
Dec 31, 2024
Owens & Minor Q4 2024 Earnings Report
Reported financial results for Q4 and full year ended December 31, 2024, and announced sale process underway for Products & Healthcare Services segment.
Key Takeaways
Owens & Minor reported financial results for the fourth quarter and year ended December 31, 2024. The company is pleased with the progress that they have made against the strategy as outlined at Investor Day in December 2023. They committed to optimizing their Products & Healthcare Services business, leveraging their leading Patient Direct platform, and building balance sheet flexibility through deleveraging. Active discussions are underway regarding the potential sale of Products & Healthcare Services (P&HS) Segment. Board of Directors authorized share repurchase program of up to $100 Million.
Total Debt Reduction of $244 Million in 2024, capping a Two-Year Total Debt Reduction of $647 Million
2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow
Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment
Board of Directors Authorizes Share Repurchase Program of Up to $100 Million
Owens & Minor
Owens & Minor
Forward Guidance
The Company issued its outlook for 2025; summarized below: Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million Adjusted EPS for 2025 to be in a range of $1.60 to $1.85
Positive Outlook
- Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion
- Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million
- Adjusted EPS for 2025 to be in a range of $1.60 to $1.85
- Gross margin of 20.75% to 21.25%
- Stable commodity prices
Challenges Ahead
- The Company’s outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
- Interest expense of $138 million to $142 million
- Adjusted effective tax rate of 29.0% to 30.0%
- Diluted weighted average shares of ~80 million
- FX rates as of 12/31/2024